CHKA and non-small cell lung carcinoma: The results showed that compared with chemo alone, CKI combined with chemo significantly reduced adverse events in patients with NSCLC (RR = 0.67, 95% CI: 0.60 to 0.74; P < 0.00001) (Figure 5).